BSX Volume Alert - BSX 13.45 Boston Scientific Corp $BSX Hit a high of 13.48 Currently 11:15 Last price 13.45 unch unch With a day low of 13.41 and a current volume of 5,961,465.
BSX Boston Scientific Corp Recent Headline News
Nevro - I Remain Cautious After A Successful Debut For This Pain Relief Company
The Value Investor - at Seeking Alpha - Tue Nov 11, 7:43AM CST
BSX: 13.46 (+0.01), NVRO: 25.50 (+0.24)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.46 (+0.01), ABT: 44.53 (+0.44), MDT: 69.19 (+0.48), CSII: 29.81 (-0.21), LMAT: 7.15 (-0.01)
Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), WAG: 67.67 (-0.11)
Medtronic launches MRI-compatible ICD system in Japan
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:49AM CST
BSX: 13.46 (+0.01), MDT: 69.19 (+0.48), STJ: 65.86 (+0.16)
Could This Obamacare Tax Be Repealed?
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 09, 7:18AM CST
Source: White House on Flickr. With the midterm elections now in the rear-view mirror, Americans can begin speculating about the policies that will come out of Washington over the next two years. Personally, I can't say I'm a huge fan of the...
ZMH: 111.36 (+0.94), BSX: 13.46 (+0.01), MDT: 69.19 (+0.48), NUVA: 43.61 (+1.14)
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), BIOS: 5.71 (+0.12)
Boston Scientific (BSX) Breaks Through Support at $13.31
Comtex SmarTrend(R) - Fri Nov 07, 12:25PM CST
Boston Scientific (NYSE:BSX) has opened bearishly below the pivot of $13.37 today and has reached the first level of support at $13.31. Analysts will be watching for a cross of the next downside pivot targets of $13.27 and $13.17.
BSX: 13.46 (+0.01)
Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), OMCL: 31.96 (-0.53)
Wright Medical Posts Wider Q3 Loss; Lowers '14 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:50AM CST
Following the earnings release, shares of Wright Medical Group Inc. (WMGI) dropped nearly 5.7% to close at $28.44 yesterday.
BSX: 13.46 (+0.01), WMGI: 28.00 (+0.03), GWPH: 74.86 (+0.91), ABAX: 53.36 (+0.42)
2 Health Care Stocks to Watch on GOP Congressional Takeover - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Nov 06, 4:02PM CST
These health care stocks could benefit if Republicans push for changes in the medical sector.
BSX: 13.46 (+0.01), SYK: 88.86 (+0.42), HUM: 134.35 (+1.89)
Technical Coverage on Health Care Equipment Stocks - Boston Scientific, Zeltiq Aesthetics, Globus Medical, Volcano, and Stryker
PR Newswire - Thu Nov 06, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ), Globus Medical Inc. (NYSE: GMED), Volcano Corporation (NASDAQ: VOLC), and Stryker Corporation (NYSE: SYK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, November 5, 2014, the NASDAQ Composite ended at 4,620.72, down 0.06%, the Dow Jones Industrial Average advanced 0.58%, to finish the day at 17,484.53, and the S&P 500 closed at 2,023.57, up 0.57%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, while the index has advanced 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
BSX: 13.46 (+0.01), ZLTQ: 27.67 (+0.01), GMED: 22.79 (+1.27), VOLC: 11.06 (+0.52), SYK: 88.86 (+0.42)
GOP Win Lifts TransCanada, Medical Device, Coal Stocks
at Investor's Business Daily - Wed Nov 05, 1:35PM CST
Prospects for approval of the Keystone XL pipeline, and for Calgary-based pipeline operator TransCanada (TRP), brightened after the GOP gained control of the Senate Tuesday. The power shift in Washington is also expected to benefit medical device...
BSX: 13.46 (+0.01), BTU: 11.14 (-0.26), MDT: 69.19 (+0.48), TRP: 49.42 (-0.03), STJ: 65.86 (+0.16), ANR: 2.57 (-0.07)
Insider Trading Alert - LLY, CRUS And BSX Traded By Insiders
at The Street - Wed Nov 05, 10:24AM CST
Stocks with insider trader activity include LLY, CRUS and BSX
BSX: 13.46 (+0.01), CRUS: 19.55 (-0.14), LLY: 68.54 (+0.19)
Republicans Grab Senate: Which Stocks Will Fare Well? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:19AM CST
The Republican win will certainly bolster stocks and give investors more chances to earn.
GD: 141.87 (+1.05), LMT: 188.18 (+1.19), MDT: 69.19 (+0.48), QDEL: 28.55 (+0.53), XOM: 96.00 (-0.28), CLF: 10.74 (-0.30), BA: 125.50 (+0.86), NUVA: 43.61 (+1.14), ANR: 2.57 (-0.07), BSX: 13.46 (+0.01), VLO: 50.75 (+0.16), BTU: 11.14 (-0.26), ABAX: 53.36 (+0.42), IMO: 47.12 (-0.38), ACI: 2.44 (-0.07)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.46 (+0.01), BCR: 164.47 (+0.60), INCY: 70.99 (+0.03), MYL: 53.75 (-0.20), AEGR: 21.65 (+0.08)
Boston Scientific To Participate In 2014 Stifel Healthcare Conference
PR Newswire - Wed Nov 05, 7:30AM CST
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New York City. Dan Brennan, executive vice president and chief financial officer, will participate in a 30-minute question and answer session regarding the company beginning at approximately 9:10 a.m. ET.
BSX: 13.46 (+0.01)
CVS Health Beats Q3 Earnings, Revenues; Narrows Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:00PM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? reported third-quarter 2014 adjusted earnings per share (EPS) of $1.15.
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), CVS: 89.90 (+0.71)
Haemonetics Q2 Earnings Beat Estimates but Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:20PM CST
Haemonetics Corporation (HAE) reported adjusted earnings of 47 cents per share in the second quarter of fiscal 2015.
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), HAE: 36.92 (+0.26)
Boston Scientific (BSX) Approaches New Downside Target of $13.17
Comtex SmarTrend(R) - Tue Nov 04, 10:15AM CST
Shares of Boston Scientific (NYSE:BSX) opened today below their pivot of $13.29 and have already reached the first level of support at $13.24. Should the shares continue to fall, the support pivots of $13.17 and $13.05 will be of interest.
BSX: 13.46 (+0.01)
Boston Scientific To Host And Webcast Investor Event
PR Newswire - Tue Nov 04, 7:30AM CST
Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and discuss data from the EVOLVE II study, the pivotal trial designed to support SYNERGY(TM) Stent System approval by the FDA. EVOLVE II data will be presented in a Late-Breaking Clinical Trial presentation on November 19 at 10:55am CT at the 2014 American Heart Association Scientific Sessions. The Boston Scientific investor event and webcast, which will include a question and answer session, is scheduled to begin at 1:00 p.m. CT and adjourn at approximately 2:00 p.m. CT.
BSX: 13.46 (+0.01)
BSX Boston Scientific Corp Recent Headline News
Nevro - I Remain Cautious After A Successful Debut For This Pain Relief Company
The Value Investor - at Seeking Alpha - Tue Nov 11, 7:43AM CST
BSX: 13.46 (+0.01), NVRO: 25.50 (+0.24)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.46 (+0.01), ABT: 44.53 (+0.44), MDT: 69.19 (+0.48), CSII: 29.81 (-0.21), LMAT: 7.15 (-0.01)
Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), WAG: 67.67 (-0.11)
Medtronic launches MRI-compatible ICD system in Japan
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:49AM CST
BSX: 13.46 (+0.01), MDT: 69.19 (+0.48), STJ: 65.86 (+0.16)
Could This Obamacare Tax Be Repealed?
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 09, 7:18AM CST
Source: White House on Flickr. With the midterm elections now in the rear-view mirror, Americans can begin speculating about the policies that will come out of Washington over the next two years. Personally, I can't say I'm a huge fan of the...
ZMH: 111.36 (+0.94), BSX: 13.46 (+0.01), MDT: 69.19 (+0.48), NUVA: 43.61 (+1.14)
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), BIOS: 5.71 (+0.12)
Boston Scientific (BSX) Breaks Through Support at $13.31
Comtex SmarTrend(R) - Fri Nov 07, 12:25PM CST
Boston Scientific (NYSE:BSX) has opened bearishly below the pivot of $13.37 today and has reached the first level of support at $13.31. Analysts will be watching for a cross of the next downside pivot targets of $13.27 and $13.17.
BSX: 13.46 (+0.01)
Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), OMCL: 31.96 (-0.53)
Wright Medical Posts Wider Q3 Loss; Lowers '14 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:50AM CST
Following the earnings release, shares of Wright Medical Group Inc. (WMGI) dropped nearly 5.7% to close at $28.44 yesterday.
BSX: 13.46 (+0.01), WMGI: 28.00 (+0.03), GWPH: 74.86 (+0.91), ABAX: 53.36 (+0.42)
2 Health Care Stocks to Watch on GOP Congressional Takeover - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Nov 06, 4:02PM CST
These health care stocks could benefit if Republicans push for changes in the medical sector.
BSX: 13.46 (+0.01), SYK: 88.86 (+0.42), HUM: 134.35 (+1.89)
Technical Coverage on Health Care Equipment Stocks - Boston Scientific, Zeltiq Aesthetics, Globus Medical, Volcano, and Stryker
PR Newswire - Thu Nov 06, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ), Globus Medical Inc. (NYSE: GMED), Volcano Corporation (NASDAQ: VOLC), and Stryker Corporation (NYSE: SYK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, November 5, 2014, the NASDAQ Composite ended at 4,620.72, down 0.06%, the Dow Jones Industrial Average advanced 0.58%, to finish the day at 17,484.53, and the S&P 500 closed at 2,023.57, up 0.57%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, while the index has advanced 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
BSX: 13.46 (+0.01), ZLTQ: 27.67 (+0.01), GMED: 22.79 (+1.27), VOLC: 11.06 (+0.52), SYK: 88.86 (+0.42)
GOP Win Lifts TransCanada, Medical Device, Coal Stocks
at Investor's Business Daily - Wed Nov 05, 1:35PM CST
Prospects for approval of the Keystone XL pipeline, and for Calgary-based pipeline operator TransCanada (TRP), brightened after the GOP gained control of the Senate Tuesday. The power shift in Washington is also expected to benefit medical device...
BSX: 13.46 (+0.01), BTU: 11.14 (-0.26), MDT: 69.19 (+0.48), TRP: 49.42 (-0.03), STJ: 65.86 (+0.16), ANR: 2.57 (-0.07)
Insider Trading Alert - LLY, CRUS And BSX Traded By Insiders
at The Street - Wed Nov 05, 10:24AM CST
Stocks with insider trader activity include LLY, CRUS and BSX
BSX: 13.46 (+0.01), CRUS: 19.55 (-0.14), LLY: 68.54 (+0.19)
Republicans Grab Senate: Which Stocks Will Fare Well? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:19AM CST
The Republican win will certainly bolster stocks and give investors more chances to earn.
GD: 141.87 (+1.05), LMT: 188.18 (+1.19), MDT: 69.19 (+0.48), QDEL: 28.55 (+0.53), XOM: 96.00 (-0.28), CLF: 10.74 (-0.30), BA: 125.50 (+0.86), NUVA: 43.61 (+1.14), ANR: 2.57 (-0.07), BSX: 13.46 (+0.01), VLO: 50.75 (+0.16), BTU: 11.14 (-0.26), ABAX: 53.36 (+0.42), IMO: 47.12 (-0.38), ACI: 2.44 (-0.07)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.46 (+0.01), BCR: 164.47 (+0.60), INCY: 70.99 (+0.03), MYL: 53.75 (-0.20), AEGR: 21.65 (+0.08)
Boston Scientific To Participate In 2014 Stifel Healthcare Conference
PR Newswire - Wed Nov 05, 7:30AM CST
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New York City. Dan Brennan, executive vice president and chief financial officer, will participate in a 30-minute question and answer session regarding the company beginning at approximately 9:10 a.m. ET.
BSX: 13.46 (+0.01)
CVS Health Beats Q3 Earnings, Revenues; Narrows Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:00PM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? reported third-quarter 2014 adjusted earnings per share (EPS) of $1.15.
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), CVS: 89.90 (+0.71)
Haemonetics Q2 Earnings Beat Estimates but Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:20PM CST
Haemonetics Corporation (HAE) reported adjusted earnings of 47 cents per share in the second quarter of fiscal 2015.
BSX: 13.46 (+0.01), ICUI: 81.73 (+9.92), ABAX: 53.36 (+0.42), HAE: 36.92 (+0.26)
Boston Scientific (BSX) Approaches New Downside Target of $13.17
Comtex SmarTrend(R) - Tue Nov 04, 10:15AM CST
Shares of Boston Scientific (NYSE:BSX) opened today below their pivot of $13.29 and have already reached the first level of support at $13.24. Should the shares continue to fall, the support pivots of $13.17 and $13.05 will be of interest.
BSX: 13.46 (+0.01)
Boston Scientific To Host And Webcast Investor Event
PR Newswire - Tue Nov 04, 7:30AM CST
Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and discuss data from the EVOLVE II study, the pivotal trial designed to support SYNERGY(TM) Stent System approval by the FDA. EVOLVE II data will be presented in a Late-Breaking Clinical Trial presentation on November 19 at 10:55am CT at the 2014 American Heart Association Scientific Sessions. The Boston Scientific investor event and webcast, which will include a question and answer session, is scheduled to begin at 1:00 p.m. CT and adjourn at approximately 2:00 p.m. CT.
BSX: 13.46 (+0.01)
